Biological therapies that target tumor necrosis factor α (TNFα), interleukin (IL)-12/IL-23 p40, IL-23p19, IL-17A, and IL-36R are increasingly used for patients with moderate to severe, refractory, and special types of psoriasis [10]. This evidence concerns the gene IL23A and psoriasis.